NEW YORK (GenomeWeb News) – Shares of Caliper Life Sciences and Genomic Health rose 30 percent each during November, as the GenomeWeb Daily News Index outperformed the broader market.
Overall, 15 of the 33 stocks in the GWDN Index rose for the month. The Index finished November up 2 percent, while the Dow Jones Industrial Average was down 1 percent, the Nasdaq was virtually flat, and the Nasdaq Biotech Index slipped 2 percent.
Caliper's share price has more than doubled this year, from its Dec. 31, 2009 close of $2.54. In mid-November, its stock was added to the Nasdaq Biotech Index.
Early in the month, it announced a collaboration with Sony DADC Austria to co-develop and manufacture plastic consumables for Caliper's next-generation microfluidics products.
Meanwhile, Genomic Health's shares traded at their highest level since March. The firm posted third-quarter revenue growth of 17 percent, beating analysts' estimates, early in the month.
GenMark Diagnostics led decliners in the Index with a 24 percent decline for November. The firm had reported a 162 percent increase in Q3 revenues and beat analysts' estimates, but its shares fell after an initial spike on the release of the results. GenMark's stock was the top performer in the Index in October, rising 46 percent.
Helicos BioSciences was removed from the GWDN Index after being de-listed from the Nasdaq Global Market in mid-November.